Protective effects of arbutin against doxorubicin-induced cardiac damage
- PMID: 38637360
- DOI: 10.1007/s11033-024-09488-4
Protective effects of arbutin against doxorubicin-induced cardiac damage
Abstract
Background: Doxorubicin is an effective antineoplastic agent but has limited clinical application because of its cumulative toxicities, including cardiotoxicity. Cardiotoxicity causes lipid peroxidation, genetic impairment, oxidative stress, inhibition of autophagy, and disruption of calcium homeostasis. Doxorubicin-induced cardiotoxicity is frequently tried to be mitigated by phytochemicals, which are derived from plants and possess antioxidant, anti-inflammatory, and anti-apoptotic properties. Arbutin, a natural antioxidant found in the leaves of the bearberry plant, has numerous pharmacological benefits, including antioxidant, anti-bacterial, anti-hyperglycemic, anti-inflammatory, and anti-tumor activity.
Methods and results: The study involved male Wistar rats divided into three groups: a control group, a group treated with doxorubicin (20 mg/kg) to induce cardiac toxicity, a group treated with arbutin (100 mg/kg) daily for two weeks before doxorubicin administration. After treatment, plasma and heart tissue samples were collected for analysis. The samples were evaluated for oxidative stress parameters, including superoxide dismutase, malondialdehyde, and catalase, as well as for cardiac biomarkers, including CK, CK-MB, and LDH. The heart tissues were also analyzed using molecular (TNF-α, IL-1β and Caspase 3), histopathological and immunohistochemical methods (8-OHDG, 4 Hydroxynonenal, and dityrosine). The results showed that arbutin treatment was protective against doxorubicin-induced oxidative damage by increasing SOD and CAT activity and decreasing MDA level. Arbutin treatment was similarly able to reverse the inflammatory response caused by doxorubicin by reducing TNF-α and IL-1β levels and also reverse the apoptosis by decreasing caspase-3 levels. It was able to prevent doxorubicin-induced cardiac damage by reducing cardiac biomarkers CK, CK-MB and LDH levels. In addition to all these results, histopathological analyzes also show that arbutin may be beneficial against the damage caused by doxorubicin on heart tissue.
Conclusion: The study suggests that arbutin has the potential to be used to mitigate doxorubicin-induced cardiotoxicity in cancer patients.
Keywords: Apoptosis; Arbutin; DNA/RNA damage; Doxorubicin; Inflammation; Oxidative stress.
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Similar articles
-
Cardioprotective effects of minocycline against doxorubicin-induced cardiotoxicity.Biomed Pharmacother. 2023 Feb;158:114055. doi: 10.1016/j.biopha.2022.114055. Epub 2022 Dec 7. Biomed Pharmacother. 2023. PMID: 36495663
-
The role of hesperidin as a cardioprotective strategy against doxorubicin-induced cardiotoxicity: The antioxidant, anti-inflammatory, antiapoptotic, and cytoprotective potentials.Open Vet J. 2023 Dec;13(12):1718-1728. doi: 10.5455/OVJ.2023.v13.i12.20. Epub 2023 Dec 31. Open Vet J. 2023. PMID: 38292716 Free PMC article.
-
Cardioprotective effects of dapsone against doxorubicin-induced cardiotoxicity in rats.Cancer Chemother Pharmacol. 2020 Mar;85(3):563-571. doi: 10.1007/s00280-019-04019-6. Epub 2020 Jan 8. Cancer Chemother Pharmacol. 2020. PMID: 31915967
-
Doxorubicin-Induced Cardiac Remodeling: Mechanisms and Mitigation Strategies.Cardiovasc Drugs Ther. 2025 Feb 26. doi: 10.1007/s10557-025-07673-6. Online ahead of print. Cardiovasc Drugs Ther. 2025. PMID: 40009315 Review.
-
The Effects and Mechanisms of Indole Derivatives in Improving Doxorubicin-Induced Cardiomyopathy.Pharmacology. 2025 Apr 26:1-12. doi: 10.1159/000546061. Online ahead of print. Pharmacology. 2025. PMID: 40288371 Review.
Cited by
-
Role of arbutin in the inhibition of FBXO5 in hepatocellular carcinoma.Discov Oncol. 2024 Dec 23;15(1):827. doi: 10.1007/s12672-024-01729-z. Discov Oncol. 2024. PMID: 39714552 Free PMC article.
References
-
- Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, Moreira PI (2009) Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267–3285 - PubMed
-
- Erfu C, Li L, Weiting Q, Tao C, Liwei M, Hemin Y, Junkun L (2024) Matrine attenuating cardiomyocyte apoptosis in doxorubicin-induced cardiotoxicity through improved mitochondrial membrane potential and activation of mitochondrial respiratory chain Complex I pathway. Biomed Pharmacother 173:116464 - PubMed
-
- Xu S, Zheng S, Ma N, Zhang H, Shi J, Huang J, Luo N, Wang M, Xiong Y (2024) Rhein potentiates doxorubicin in treating triple negative breast cancer by inhibiting cancer-associated fibroblasts. Biochem Pharmacol 223:116139 - PubMed
-
- Hao G, Yu Y, Gu B, Xing Y, Xue M (2015) Protective effects of berberine against doxorubicin-induced cardiotoxicity in rats by inhibiting metabolism of doxorubicin. Xenobiotica 45:1024–1029 - PubMed
-
- Olson RD, Boerth RC, Gerber JG, Nies AS (1981) Mechanism of adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29:1393–1401 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous